Secondary analysis of CLEAR Outcomes: in 1624 statin-intolerant patients with PAD, bempedoic acid vs placebo reduced first major adverse limb events (HR 0.64, 95% CI 0.44–0.93; 8.3% with placebo over median 40.6 months) and total limb events (RR 0.55).
Secondary analysisn = 1,624
Bonaca et al. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial